Format

Send to

Choose Destination
Nutrients. 2019 Jul 31;11(8). pii: E1761. doi: 10.3390/nu11081761.

Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study.

Author information

1
Endocrinology and Nutrition Clinical Management Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
2
Endocrinology and Nutrition Clinical Management Unit, University Hospital of Jaén, 23007 Jaén, Spain.
3
Department of Health Sciences, School of Health Sciences, University of Jaén, 23071 Jaén, Spain.
4
Digestive Diseases Clinical Management Unit, University Hospital of Jaén, 23007 Jaén, Spain.
5
Department of Signal Theory, Networking, and Communications, University of Granada, 18071 Granada, Spain.
6
Department of Microbiology, University Hospital Campus de la Salud, 18016 Granada, Spain.
7
Instituto de Investigación Biosanitaria ibs. GRANADA, 18012 Granada, Spain.
8
Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.
9
Institute of Nutrition and Food Technology "José Mataix", Center of Biomedical Research, University of Granada, 18016 Granada, Spain.
10
CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain.
11
Biosearch Life, 18004 Granada, Spain.
12
Instituto de Investigación Biosanitaria ibs. GRANADA, 18012 Granada, Spain. gomezll@ugr.es.
13
Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain. gomezll@ugr.es.
14
Institute of Nutrition and Food Technology "José Mataix", Center of Biomedical Research, University of Granada, 18016 Granada, Spain. gomezll@ugr.es.
15
CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain. gomezll@ugr.es.

Abstract

Previous studies have reported that probiotics may improve clinical and inflammatory parameters in patients with obesity and metabolic syndrome (MetS). Lactobacillus (L.) reuteri V3401 has shown promising results on the components of MetS in animal studies. We aimed to evaluate the effects of L. reuteri V3401 together with healthy lifestyle recommendations on adult patients with MetS.

METHODS:

We carried out a randomized, crossover, placebo-controlled, single-center trial in which we included 53 adult patients newly diagnosed with MetS. Patients were block randomly allocated by body mass index (BMI) and sex to receive a capsule containing either the probiotic L. reuteri V3401 (5 × 109 colony-forming units) or a placebo once daily for 12 weeks. Anthropometric variables, biochemical and inflammatory biomarkers, as well as the gastrointestinal microbiome composition were determined.

RESULTS:

There were no differences between groups in the clinical characteristics of MetS. However, we found that interleukin-6 (IL-6) and soluble vascular cell adhesion molecule 1 (sVCAM-1) diminished by effect of the treatment with L. reuteri V3401. Analysis of the gastrointestinal microbiome revealed a rise in the proportion of Verrucomicrobia.

CONCLUSIONS:

Consumption of L. reuteri V3401 improved selected inflammatory parameters and modified the gastrointestinal microbiome. Further studies are needed to ascertain additional beneficial effects of other probiotic strains in MetS as well as the mechanisms by which such effects are exerted.

KEYWORDS:

Lactobacillus reuteri V3401; gastrointestinal microbiome; metabolic syndrome; obesity; probiotics

PMID:
31370223
DOI:
10.3390/nu11081761
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center